Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30

$18.77+0.07 (+0.37%)

Close on Nov 13, 2026Market cap $2.13BP/E –Yield –

Immunome r&d expenses

Research and development expenses are spending on new products and technology.

Immunome's R&D Expenses for the twelve months ending Mar 31, 2026 was $186.80M, up 23.7% year over year. For fiscal 2025 it was $177.29M, up 36.9% from the year before. The highest annual figure on record is $177.29M in fiscal 2025.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$177.29M	+36.9%
FY2024	Dec 31, 2024	$129.54M	+461.1%
FY2023	Dec 31, 2023	$23.09M	-0.8%
FY2022	Dec 31, 2022	$23.27M	+64.9%
FY2021	Dec 31, 2021	$14.11M	+88.5%
FY2020	Dec 31, 2020	$7.49M	-15.2%
FY2019	Dec 31, 2019	$8.82M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q1 FY2026	Mar 31, 2026	$46.38M	+25.8%
Q4 FY2025	Dec 31, 2025	$50.77M	+6.0%
Q3 FY2025	Sep 30, 2025	$49.19M	+32.2%
Q2 FY2025	Jun 30, 2025	$40.45M	+39.1%
Q1 FY2025	Mar 31, 2025	$36.87M	+139.9%
Q4 FY2024	Dec 31, 2024	$47.89M	+396.9%
Q3 FY2024	Sep 30, 2024	$37.20M	+873.1%
Q2 FY2024	Jun 30, 2024	$29.08M	+408.8%
Q1 FY2024	Mar 31, 2024	$15.37M	+292.8%
Q4 FY2023	Dec 31, 2023	$9.64M	+126.6%
Q3 FY2023	Sep 30, 2023	$3.82M	-26.8%
Q2 FY2023	Jun 30, 2023	$5.72M	-0.0%
Q1 FY2023	Mar 31, 2023	$3.91M	-51.6%
Q4 FY2022	Dec 31, 2022	$4.25M	-3.0%
Q3 FY2022	Sep 30, 2022	$5.23M	+15.8%
Q2 FY2022	Jun 30, 2022	$5.72M	+76.8%
Q1 FY2022	Mar 31, 2022	$8.08M	+308.2%
Q4 FY2021	Dec 31, 2021	$4.39M	+139.0%
Q3 FY2021	Sep 30, 2021	$4.51M	+174.5%
Q2 FY2021	Jun 30, 2021	$3.23M	+70.9%
Q1 FY2021	Mar 31, 2021	$1.98M	-6.4%
Q4 FY2020	Dec 31, 2020	$1.84M	-24.5%
Q3 FY2020	Sep 30, 2020	$1.64M	-26.4%
Q2 FY2020	Jun 30, 2020	$1.89M	–
Q1 FY2020	Mar 31, 2020	$2.12M	–
Q4 FY2019	Dec 31, 2019	$2.43M	–
Q3 FY2019	Sep 30, 2019	$2.23M	–